Dr Stephen Jeffery Groote Schuur Hospital Cape Town

Slides:



Advertisements
Similar presentations
Desmopressin: PRN Treatment in OAB Prospective, randomised, multi-centre, multinational, double-blind, placebo controlled observational study Prospective,
Advertisements

Pelvic Floor Dysfunction
Onabotulinum toxin for Pelvic pain Philip Toozs-Hobson Consultant Urogynaecologist Birmingham UK.
Revolution in Asian drug development: A Korea and Japan experience Henk de Koning Gans, MD VP, Process Management Global Development Japan Pharmacia KK,
Botox® for the overactive bladder -The evidence Philip Toozs-Hobson Consultant Urogynaecologist.
Botulinum toxin-A for overactive bladder and detrusor overactivity Douglas Tincello Professor of Urogynaecology Prolapse & Incontinence Group, University.
Urinary Incontinence Kieron Durkan GPST 1.
Incontinence in children, a symptom complex Daytime incontinence (OAB), enuresis Dyschezia, incontinence for stools Pain 30-35% of these children with.
Doha, March 12th 2008 The magic magnetic chair- how to facilitate best Daniela Marschall-Kehrel, Frankfurt.
The Overactive Bladder
OnabotulinumtoxinA for Urinary Incontinence from Neurogenic Detrusor Overactivity.
Urodynamic Findings and Diagnosis in Aging People
Overactive Bladder: Diagnosis and Treatment Chase Kenyon Sovell, MD Urology Associates May 30 th, 2007 Pearls of Plumbing Seminar.
Urinary incontinence in women October Changing clinical practice NICE guidelines are based on the best available evidence The Department of Health.
OnabotulinumtoxinA (Botox®) for the Treatment of Overactive Bladder
Urinary Incontinence Victoria Cook
Physiotherapy approaches for urgency and urge incontinence Liz Childs Pelvic Health Physiotherapist.
Urinary Incontinence Dr Asso F.A.Amin MRCP(UK),MRCGP,MRCPE.
Paediatric Urotherapy Training Frances Shit NS, MSc (Hons), ET, Dept. of Surgery, PWH, CUHK HKSAR.
Buddhist Tzu Chi General Hospital
Luigi Piccinini M.D., PM&R Scientific Institute «Medea» Bosisio Parini (LC) Italy.
Disability and Incontinence Patient assessment Patient management.
LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.
Ultrasound Guided Botulinum Toxin Injection for Sialorrhoea in Parkinson’s Disease; Evidence, Technique and Outcomes Background Sialorrhoea: inability.
A Double-Blind, Randomized, Placebo-Controlled Study of Calcium Glycerophosphate Dietary Supplement in Patients with Overactive Bladder Michael J. Kennelly,
GERIATRICS : UI Dr. Meg-angela Christi Amores. URINARY INCONTINENCE  major problem for older adults, afflicting up to 30% of community-dwelling elders.
 Stephen T Jeffery University of Cape Town, South Africa Urogynaecology and laparoscopy clinic
Keeping the right patients away from hospital
Comments for Anatomy, Physiology and Urodynamics Hann-Chorng Kuo Department of Urology Buddhist Tzu Chi General Hospital.
Sharon English Urologist Christchurch
ROLE OF PERCUTANEOUS TIBIAL NERVE STIMULATION (PTNS) IN THE TREATMENT OF NEUROGENIC OVERACTIVE BLADDER SYNDROME Perugia G., Corongiu E., Borgoni.
Over active bladder drug treatment Mark Weatherall University of Otago Wellington.
Jeffrey P. Weiss, MD, FACS Professor and Chair Department of Urology
Update On OAB Joon Chul Kim The Catholic University of Korea.
PROF. Rosita Aniuliene LITHUANIAN UNIVERSITY OF HEALTH SCIENCES President of Lithuanian Association of Urogynecology.
Prescribing information is available at this meeting MODULE 3 TREATMENT OPTIONS AND EXPECTATIONS 1 DET 808.
Controlling Urine Leakage What You Need To Know David Spellberg MD,FACS Controlling Urine Leakage What You Need To Know David Spellberg MD,FACS.
INTERSTIM ® THERAPY for Urinary Control. What are Bladder Control Problems? Broad range of symptoms –May leak small or large amount of urine –May leak.
International Neurourology Journal 2015;19: Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome Chun-Hou.
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara.
โดย เภสัชกรณัฐวุฒิ จรีบุญ สมโภช. OAB affects 33 million people in the United States (17% of American adults) more common in women and in older people.
The Problem Bladder: UTI, the Unstable bladder and Mixed Incontinence Stephen Jeffery/Pieter Kruger Groote Schuur Hospital UCT Private Academic Hospital.
Volume 50, Issue 3, Pages (September 2006)
Stephen Jeffery Urogynaecologist Groote Schuur Hospital and UCT
International Neurourology Journal 2013;17:
International Neurourology Journal 2015;19:
Volume 41, Issue 3, Pages (March 2002)
Algorithms of Incontinence Management Men
Urinary Symptoms in the Female
Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection 
International Neurourology Journal 2015;19:
Success of a repeated tined lead trial in a refractory OAB population
Predictors of Longterm Sacral Nerve Stimulation Failures
497 MIRABEGRON IS A SAFE AND EFFECTIVE TREATMENT FOR PARKINSON’S DISEASE PATIENTS WITH STORAGE SYMPTOMS REFRACTORY TO ANTIMUSCARINICS Soto Troya I1 , Park.
Management of Male OAB; Current Status in Japan
Jean-Jacques Wyndaele  European Urology Supplements 
OB,GYN / Fellowship of Pelvic Floor
Bladder Dysfunction Associated With Parkinson’s Disease
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Nat. Rev. Urol. doi: /nrurol
Portable Biofeedback for Bladder Control
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report1  Dennis D Dykstra, MD,
Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation  Apostolos Apostolidis, Axel Haferkamp,
Volume 52, Issue 6, Pages (December 2007)
International Neurourology Journal 2016;20:40-46
Economic and Social Impact of OAB
Comparison of protocols for tibial nerve electrical stimulation for the treatment of overactive bladder: clinical trial randomized blind Pierre ML, Toscano.
Women’s & Men’s Health Physiotherapy
Medical Scientific Experts
Presentation transcript:

Dr Stephen Jeffery Groote Schuur Hospital Cape Town Recent Advances in the Management of the Overactive Bladder Chairmen ladies and gentleman thank you for allowing me to give you an update on this topic. I will focus on Botulinum toxin since a lot has come out recently on its use in OAB. Dr Stephen Jeffery Groote Schuur Hospital Cape Town

Relative proportions of incontinence by age Stress urinary incontinence (SUI) Total 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89 90+ Mixed urinary incontinence (MUI) 80 60 40 20 Urge urinary incontinence (UUI) Percentage of incontinent women (%) KEY POINT: Urinary incontinence (UI) is a common condition in women, and its prevalence increases with age. Younger and middle aged women with UI are more likely to have stress UI (SUI) than urge UI (UUI) or mixed UI.1 In older women, mixed UI and UUI are proportionally more prevalent than SUI.1 ADDITIONAL INFORMATION: A Norwegian survey of 27,936 women aged 20 years found an overall prevalence of UI of 25%.1 While the lowest prevalence was found among the youngest age group and the highest prevalence among the oldest age group, a peak was also seen around middle age and the onset of the menopause (50–54 years).1 REFERENCE: Hannestad YS et al. J Clin Epidemiol 2000; 53: 1150–1157. Age (years) n=6876 Hannestad YS et al. J Clin Epidemiol 2000; 53: 1150–1157. Reproduced with permission from Professor David Castro-Diaz.

Why do patients stop taking antimuscarinic therapy? International web survey 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Female ≤55 Years of Age 57 30 2 9 Female >55 Years of Age 47 39 8 4 Male 50 24 3 18 In Employment/Activity Working 50 31 7 9 Retired/Unemployment 50 30 4 14 OAB Dry 58 26 2 10 Pure UUI 61 24 3 10 Mixed UI 66 16 13 2 Insufficient efficacy Intolerable side effects Dosing convenience Other reasons This was an international quantitative web survey of practicing doctors, including urology/gynaecology specialists. Lack of efficacy is the major reason for failure of first-line antimuscarinic therapy Reference: Global Market Research Study (Yamanouchi Pharma Ltd, December 2003:n=736).

What Percentage of Urge Incontinent Patients achieve Long-Term Benefit From Drugs? 10 20 30 40 50 60 70 80 90 100 All Patients With DO and UI Cured/ Improved Responders Using Drugs >6 Months Urge Incontinent Patients (%) This slide shows that non-compliance is a problem with anticholinergics, even in those patients that experience an improvement of urge incontinence. Non-compliance is mainly due to muscarinic side effects. Kelleher et al. Br J Obstet Gyn. 1997;104:988-93.

Persistence on Specific Medications for OAB Based on Prescription Data Percent Months Chui M, et al. Value in Health. 2004;7:366.

When Anticholinergics Fail Sacroneuromadulation PTNS Acupuncture Physiotherapy Botox

Botulinum Toxin Introduction Options Neuromodulation Augmentation / Ileocystoplasty Botulinum Toxin The options for these patients include neuromodulation. As we will hear from Mr drake later – these modalities are expensive, not readliy available and reqire an infrastructure. The other option is surgery in the form of aug/ cystplasty. These operations have a morbidity and in many cases – the patient is condemned to a life of voiding dysfunction. Over the last six years Botulinum Toxin has become an alternative in this group of patiets and many physicians will now place it here as a option before proceding to Neuromodulation or surgery or as an alternative.

Introduction 21st Century Penicillin for the Bladder ! Schurch 2000 21 Neurogenic Detrusor Overactivity (NDO) Botox 200-300u 17/19 achieved continence Bladder capacity increased 296ml to 480ml Reflex volume 215ml to 415 ml Brigitte Schurch’s group from Switzerland was the first to publish on the use of Botox in these patients. They looked at 21 NDO. They had previously done a dose finding study on 15 patients and that is how they came to the dose of 200-300 units. Of the 19 patients 17 achieved total continence. There were remarkable URO findings with capacity increasing from 296 to 480 ml and reflex voume 215 to 415. These results have been repeated in many other studies since then and at a recent meeting in Schurch has been quoted as saying that Botox…………………… 21st Century Penicillin for the Bladder ! Schurch et al . J. Urol 2000; 164: 692-697

Introduction Clostridium botulinum Gram positive Anaerobic 1 g kills I million people Botulinum toxin comes from Clostridium botulinum. It is a Gram positive, anaerobic bacteria which is commonly found in the soil. Of note, 1 g of toxin can kill 1 million people.

Hence its potential as a biological weapon.

Introduction 1946 Purified botulinum toxin type A in a crystalline form (Schantz) 1960s Neuromuscular toxin (Schantz) 1980 Strabismus (Scott) Amongst those who have contributed to the science of botulinum toxin, credit must be given to Schantz who purified the toxin and enabled its mass production. Despite being an army officer, he advocated its use in medicine. Its first clinical use was in 1980 when it was used in strabismus.

Types 7 Subtypes A, B, C, D, E, F, G Only A and B available commercially There are 7 subtypes However only and B are available commercially

Types Botulinum A Botulinum B Botox® (Allergan Inc.) Dysport® (Ipsen Pharma) Botulinum B Neurobloc ® (Solstice Neurosciences Inc.) Many of us flippantly refer to Botulium products as Botox. However Botox is the Botulnum A product made by allergan. There is an alternative called Dysport and in fact more Dysport is used than Botox in tne UK. Botulinum B is marketed by Solstice. In OAB most of the studies have used Botulum A – B seems to have a shorter duration of action and is reserved for patients with resistance

Botulinum Toxin A Botox® Dysport ® MW (kDa) 900 Target protein SNAP 25 Units / vial 100 500 Price / vial ~£135 ~£173 Dose IDO ~200 units ~500 unit NDO ~300 units ~750 units Two commercial preparations of Botulinum toxin A anre Botox and Dysport and this summarises their charactistics. Essentially Botox is about 3x more potent than Dysport ie . You need three x more to kill a mouse than Botox.

Dosages Botox Dysport NDO 300u IDO 200u 500 to 1000u Fewer studies There is a lot more evidence for Botox than for Dysport and most studies use 300 for NDO and 200 for IDO. Exact dosage for Dysport is less clear with dosages ranging from 500 to 1000.

Administration Rigid Flexible With regard to administration, all that is required are a cystoscopy and an appropriate needle. You can use either a rigid or flexible cystoscope. Anaesthesia ranges from GA to sedation to simply local anaesthetic. Flexible

Administration The needle option also ranges from a simple needle that is through to a fine 26G olympus needle.

Administration Normal Saline Do not shake . Most of us use normal saline to dilute the Botulinum because some reports suggest pain …. Also – when reconstititing the botox – do not shake it since it is suggested that it breaks the bonds.

Administration Trigone or not? Lucioni et al Karsenty et al 16 intratrigonal and 24 trigone sparing Similar results at 3 weeks & 6 months on UDI and SIIQ Karsenty et al VCU 1hr before & @ 6 weeks N=10 No new cases of reflux with similar efficacy Most reports have avoided injecting the trigone because of the theoretical risk of reflux . However a styudy by Smith et al from the states specifically injected the trigone and no incidence of pyelonephritis. Lucioni et al Can J Urol 2006;13(5): 3291-5. Karsenty et al J Urol 2007; 177(3):1011-4

Contraindications Neuromuscular Disorders Previous Failure of Botulinum Injections Bleeding Tendencies We tend to avoid giving it in patients with

Efficacy: NDO A large amount of data has emerged over the few years suggesting excellent efficaccy in NDO.

Efficacy: NDO Schurch 2005 BOTOX N=59 (NDO) Double blind placebo controlled parallel group study Scurch et al reported again in 2005 59 NDO patients. This was a Schurch et al J Urol 2005; 174: 196-200.

Efficacy: NDO Schurch 2005 BOTOX Dose F u Urodynamics Incontinence episodes Dry QOL 300u (n=19) 200u placebo (n=21) 6 m Increase in MCC, RV Decrease in Max Det Pressure 50 % reduction for 200 and 300u 49% Mean I-QOL scoes improved (p<0.002) They gave patients either ………………. And up to 6 month FU there was a 50 % reduction in IE with 49% reporting being dry. Profound improvements in QOL Schurch et al J Urol 2005; 174: 196-200.

Increase in Maximum Cystometric Capacity (MCC) Mean increase in MCC from baseline (in ml) The urodynamic findings compared to placebo were remarkable at with highly significant increases in in MCC at 2 , 6 and 24 weeks compared to placebo. Schurch et al J Urol 2005; 174: 196-200.

Efficacy: NDO Reitz 2004 Large European study 10 Centres N=231(NDO) BOTOX Reitz 2004 Large European study 10 Centres N=231(NDO) 12 week and 24 week follow up The largest study reporting on Botox was by reitz et al who looked at 231 NDO patients with follow up at 12 and 24 weeks Reitz et al Eur Urol 2004; 45: 510-515.

Efficacy: NDO Reitz et al 2005 Dose F u Urodynamics Dry Botox 300u 3m & 9 m Increase in MCC, RV and compliance 79% @ 3 m 31% @ 9 m Again very high rates of patiets reporting dry with significant increses in urodynamic findings

Efficacy: NDO BOTOX Study N Dose FU Improved Dry Urodynamics Kuo 2005 24 BTX 200u 3m & 6m 70 % improved 25% Increased Reflex volume and MCC Klaphajone 2005 10 NDO BTX 300 9 70% Increased MCC, compliance, reflex volume, decrease in detrusor pressure Schulte-Baukloh 2006 16 MS Reduction in daily pad use from 1.75 to 1.08 (4 weeks) and 0.63 (3 months) Increased Reflex volume and MCC. Decreased Detrusor pressure Other studies reporting on Botox in NDO again with dry rates ranging from 25 with 200u to 70 with 300u. This study looked at pad use showing a reduction to 0.63 at 3 months

Hence its potential as a biological weapon.

Introduction 1946 Purified botulinum toxin type A in a crystalline form (Schantz) 1960s Neuromuscular toxin (Schantz) 1980 Strabismus (Scott) Amongst those who have contributed to the science of botulinum toxin, credit must be given to Schantz who purified the toxin and enabled its mass production. Despite being an army officer, he advocated its use in medicine. Its first clinical use was in 1980 when it was used in strabismus.

Types 7 Subtypes A, B, C, D, E, F, G Only A and B available commercially There are 7 subtypes However only and B are available commercially

Types Botulinum A Botulinum B Botox® (Allergan Inc.) Dysport® (Ipsen Pharma) Botulinum B Neurobloc ® (Solstice Neurosciences Inc.) Many of us flippantly refer to Botulium products as Botox. However Botox is the Botulnum A product made by allergan. There is an alternative called Dysport and in fact more Dysport is used than Botox in tne UK. Botulinum B is marketed by Solstice. In OAB most of the studies have used Botulum A – B seems to have a shorter duration of action and is reserved for patients with resistance

Botulinum Toxin A Botox® Dysport ® MW (kDa) 900 Target protein SNAP 25 Units / vial 100 500 Price / vial ~£135 ~£173 Dose IDO ~200 units ~500 unit NDO ~300 units ~750 units Two commercial preparations of Botulinum toxin A anre Botox and Dysport and this summarises their charactistics. Essentially Botox is about 3x more potent than Dysport ie . You need three x more to kill a mouse than Botox.

Dosages Botox Dysport NDO 300u IDO 200u 500 to 1000u Fewer studies There is a lot more evidence for Botox than for Dysport and most studies use 300 for NDO and 200 for IDO. Exact dosage for Dysport is less clear with dosages ranging from 500 to 1000.

Administration Rigid Flexible With regard to administration, all that is required are a cystoscopy and an appropriate needle. You can use either a rigid or flexible cystoscope. Anaesthesia ranges from GA to sedation to simply local anaesthetic. Flexible

Administration The needle option also ranges from a simple needle that is through to a fine 26G olympus needle.

Administration Normal Saline Do not shake . Most of us use normal saline to dilute the Botulinum because some reports suggest pain …. Also – when reconstititing the botox – do not shake it since it is suggested that it breaks the bonds.

Administration Trigone or not? Lucioni et al Karsenty et al 16 intratrigonal and 24 trigone sparing Similar results at 3 weeks & 6 months on UDI and SIIQ Karsenty et al VCU 1hr before & @ 6 weeks N=10 No new cases of reflux with similar efficacy Most reports have avoided injecting the trigone because of the theoretical risk of reflux . However a styudy by Smith et al from the states specifically injected the trigone and no incidence of pyelonephritis. Lucioni et al Can J Urol 2006;13(5): 3291-5. Karsenty et al J Urol 2007; 177(3):1011-4

Contraindications Neuromuscular Disorders Previous Failure of Botulinum Injections Bleeding Tendencies We tend to avoid giving it in patients with

Efficacy: NDO A large amount of data has emerged over the few years suggesting excellent efficaccy in NDO.

Efficacy: NDO Schurch 2005 BOTOX N=59 (NDO) Double blind placebo controlled parallel group study Scurch et al reported again in 2005 59 NDO patients. This was a Schurch et al J Urol 2005; 174: 196-200.

Efficacy: NDO Schurch 2005 BOTOX Dose F u Urodynamics Incontinence episodes Dry QOL 300u (n=19) 200u placebo (n=21) 6 m Increase in MCC, RV Decrease in Max Det Pressure 50 % reduction for 200 and 300u 49% Mean I-QOL scoes improved (p<0.002) They gave patients either ………………. And up to 6 month FU there was a 50 % reduction in IE with 49% reporting being dry. Profound improvements in QOL Schurch et al J Urol 2005; 174: 196-200.

Increase in Maximum Cystometric Capacity (MCC) Mean increase in MCC from baseline (in ml) The urodynamic findings compared to placebo were remarkable at with highly significant increases in in MCC at 2 , 6 and 24 weeks compared to placebo. Schurch et al J Urol 2005; 174: 196-200.

Efficacy: NDO Reitz 2004 Large European study 10 Centres N=231(NDO) BOTOX Reitz 2004 Large European study 10 Centres N=231(NDO) 12 week and 24 week follow up The largest study reporting on Botox was by reitz et al who looked at 231 NDO patients with follow up at 12 and 24 weeks Reitz et al Eur Urol 2004; 45: 510-515.

Efficacy: NDO Reitz et al 2005 Dose F u Urodynamics Dry Botox 300u 3m & 9 m Increase in MCC, RV and compliance 79% @ 3 m 31% @ 9 m Again very high rates of patiets reporting dry with significant increses in urodynamic findings

Efficacy: NDO BOTOX Study N Dose FU Improved Dry Urodynamics Kuo 2005 24 BTX 200u 3m & 6m 70 % improved 25% Increased Reflex volume and MCC Klaphajone 2005 10 NDO BTX 300 9 70% Increased MCC, compliance, reflex volume, decrease in detrusor pressure Schulte-Baukloh 2006 16 MS Reduction in daily pad use from 1.75 to 1.08 (4 weeks) and 0.63 (3 months) Increased Reflex volume and MCC. Decreased Detrusor pressure Other studies reporting on Botox in NDO again with dry rates ranging from 25 with 200u to 70 with 300u. This study looked at pad use showing a reduction to 0.63 at 3 months

What about Dysport in NDO? Ruffion et al 45 NDO Dysport 500 or 1000u If unsuccessful further 1000u (24%) 76% dry No difference between 500u and 1000u There are to my knowledge only three studies reporting on the other Botulinum product in OAB and all in Neourgenics. Ruffion used 500 or 1000u . If the patients no symptoms they were retreated and this was necessary in 24%. 76% reported being dry with no difference in initial efficacy between 500 and 1000u. Ruffion et al. BJU Int 2006; 97: 1030-1034

What about Dysport in NDO? Ruffion et al 1 women muscle weakness Mean duration 1000u - 10.4 months 500u - 4.83 months Ideal dose ? 750u However 1 women developed muscle weakness following 100u and the mean duration was -----. Ideal dose of 750 in NDO/ Ruffion et al. BJU Int 2006; 97: 1030-1034

Efficacy: NDO Dysport Study N Dose FU Improved Dry Urodynamics Patki 37 Dysport 1000u 7 m Improved ICIQ Reduced AC use by 80% 82% Increased MCC and decreased voiding pressure The only other study of dysport is by Patki et al where they used 1000 u with high contience rates at 7m follow up of 82%

Efficacy: IDO Follwing the success in NDO a number of studies began looking at Idiopaths. The problem with IDO is the risk of voiding dysfunction – since unlike the NDO most of these patients have normal voiding function

Efficacy IDO : RCT Sahai et al BOTOX RCT 35 IDO Double blind placebo controlled study 16 Botox 200u, 18 Placebo Significant improvements in frequency (p=0.003), urge incontinence (p=0.008) at 12 weeks 4 weeks 12 weeks MCC +144ml (p<0.0001) +96ml (p=0.0001) Sahai et al J Urol 2007; 177(6): 2231-36

Efficacy: IDO Popat 2004 44 NDO and 31 IDO NDO 300u Botox IDO 200u Botox 4 week and 16 week follow up Popat et al at Quenns squre looked at Botox in ………………. Using a lower dose of 200u to avoid voiding dysfunction Popat et al J Urol 2005; 174: 984-989.

Efficacy: NDO BOTOX Dose FU Improved Dry Urodynamics NDO BTX 300u 4 m ISC NDO BTX 300u 4 m 70 % improved 4weeks 64% NDO 16weeks 55% NDO Increased Reflex volume and MCC 69% IDO BTX 200u 4m 54% IDO 57% IDO 19% After 4 m – comparavle dry rates between the two with a 19% incidence if CISC. Popat et al J Urol 2005; 174: 984-989.

Percentage change in leak: Popat et al. This graph demonstres the change in leak between the two grouos again demonstaring compareble efficacy.

Efficacy: IDO BOTOX Study N Dose FU Improved QOL Urodynamics Voiding Dysf Schulte-Baukloh 2005 44 BTX 300u 9m Daily Pad use reduced 4.2 to 2.4 per day Improvements in UDI-6, SSI, SII up to 6 months Increased RV, MCC and reduced detrusor pressure None Werner 2005 26 BTX 100 9 69% at 4 weeks 80% at 12 weeks Improvement on all urge related parameters on KHQ Increased MCC, compliance, decreased DO, 2 ISC Rajkumar 15 300u 6 Improved on all domains in KHQ and BFLUTS Increased MCC, FDV, Reflex volume Other groups have also looked at Botox in IDO with significant imorovements and low voiding dysfunction

Efficacy: IDO Dysport * * * * * * * Weekly incontinence episodes * * Weekly incontinence episodes improved up to 9 months Jeffery et al BJU 2007; 174: 984-989.

Results: Urodynamics Jeffery et al BJU 2007; 174: 984-989. We demonstrated improvements in urodynamics but none of these were statistically significant. Detrusor contractons were obliterated in 40$ of the cohgort however. Jeffery et al BJU 2007; 174: 984-989.

Results: Voiding Dysfunction There was, however a high rate of voiding dysfunction in this cohort with 42% of patients neeing to self-catherise at 6 weeks. Jeffery et al BJU 2007; 174: 984-989.

Efficacy Repeat Injections So we know Botulnum works but its effect is short with about a 9 month duration. What about giving it again?

Efficacy Repeat Injections: NDO Study N Dose FU Improved Urodynamics Grosse 66 Repeat Botox 300u Dysport750 u or 1000u 15m Subjective high satisfaction rates Similar efficacy Increased MCC and Reflex volume In a study using both Botox 300u and Dysport 750 and 100. Grosse et al repeated it in 66 patients up to 7 times. A number of inteseting points emerge. The Dysport and Botox had similar efficacy and CMG findings. $ patients in the Dysport group developed muscle weakness Transient Muscle weakness in 4 patients after Dysport 1000u Grosse et al. Eur Urol 2005; 47: 653-659

Efficacy Repeat Injections: NDO Time between injections (in months) However- the time between injections remained consistent Grosse et al. Eur Urol 2005; 47: 653-659

Efficacy Sensory Urgency

Efficacy: No Do on CMG Study N Dose FU Improved QOL Urodynamics Voiding Dysf Schulte-Baukloh 2005 7 BTX 300u 6m Daily Pad use reduced Improved UDI -6, SII scores No significant changes None There has been one study looking at its efficacy in pateints with normal CMG. And showed improvements on pad and QOL testing Schulte-Baukloh et al. Urology 2005; 66(1): 82-87

Long Term Efficacy Kuschel et al 2 yr follow up Botox 100 u N=26 11 single injection 1 primary failure 3 lost to follow up 11 repeat injection There has been one study looking at cost by Vinay Kalsi et al and they estimated the …………………

Long Term Efficacy Kuschel et al 11 single injection 4 very satisfied 7 had other treatments There has been one study looking at cost by Vinay Kalsi et al and they estimated the …………………

Newer data: Site of injection Kuo et al N=45 Suburothelial vs Detrusor vs Trigonal Injection VCU at 3 month showed no reflux Success Suburothelial 80% Detrusor 93% Trigonal Injection 67% There has been one study looking at cost by Vinay Kalsi et al and they estimated the …………………

Cost Effectiveness Kalsi et al IDO £745 per treatment NDO £874 per treatment Viewed in the context of the alternatives Sacroneuromodulation Cystoplasty There has been one study looking at cost by Vinay Kalsi et al and they estimated the …………………

Conclusion Botulinum Toxin A – highly effective Improvements in multiple parameters No loss of efficacy with repeat injections Main problem is voiding dysfunction

Issues Correct dose esp dysport Trigonal injections Sphincter injections No. and dilution of injections